Antisense oligonucleotides: towards clinical trials

Trends in Biotechnology
S Agrawal

Abstract

Antisense oligonucleotides have the ability to selectively block disease-causing genes, thereby inhibiting production of disease-associated proteins. The specificity and application of antisense oligonucleotides have been strongly validated in animal models for various disease targets. Based on the pharmacological, pharmacodynamic and pharmacokinetic profiles, the first generation of antisense oligonucleotides--phosphorothioates--have reached the stage of human clinical trials for various diseases. While ongoing human clinical trials are being carried out to further establishing the safety and efficacy of these oligonucleotides, the experience gained is providing a basis for designing a second generation of antisense oligonucleotides.

References

Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·P C Zamecnik, M L Stephenson
Oct 28, 1992·Annals of the New York Academy of Sciences·S AgrawalP C Zamecnik
Oct 28, 1992·Annals of the New York Academy of Sciences·J TemsamaniS Agrawal
Jan 1, 1992·Antisense Research and Development·S Agrawal, J Y Tang
May 1, 1992·Trends in Biotechnology·S Agrawal
Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·W S MarshallM H Caruthers
Nov 16, 1992·Biochemical and Biophysical Research Communications·H ItohV J Dzau
Dec 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J LisziewiczR Gallo
Nov 1, 1992·Japanese Journal of Cancer Research : Gann·E KuramotoT Tokunaga
Sep 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalJ Y Tang
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalT Pederson
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalP C Zamecnik
Feb 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·E L WickstromE Wickstrom
Nov 6, 1973·Naunyn-Schmiedeberg's Archives of Pharmacology·T StauR Taugner
Jan 1, 1995·Antisense Research and Development·S K SrinivasanP L Iversen
Jan 1, 1995·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·T SkutellaG F Jirikowski
Apr 6, 1995·Nature·A M KriegD M Klinman
Jan 1, 1995·Clinical Pharmacokinetics·S AgrawalJ Tang
Jan 1, 1995·Journal of Clinical Laboratory Analysis·S K Srinivasan, P Iversen
Apr 11, 1995·Nucleic Acids Research·J Y MalteseR Narayanan
Feb 1, 1995·Current Opinion in Biotechnology·S Agrawal, R P Iyer
Jan 1, 1994·Antisense Research and Development·U M SarmientoR Narayanan
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·N M Dean, R McKay
Jan 1, 1994·Antisense Research and Development·J TemsamaniS Agrawal
May 9, 1994·FEBS Letters· Rykova EYuV V Vlassov

❮ Previous
Next ❯

Citations

May 18, 1999·International Journal of Cancer. Journal International Du Cancer·M RodríguezC J Ciudad
Sep 25, 1999·Journal of Cellular Physiology·U GalderisiA Giordano
May 2, 2003·Archives of Pharmacal Research·Yoon S Cho-Chung
Mar 17, 2004·Biochimica Et Biophysica Acta·Yoon S Cho-Chung
Mar 21, 2003·Biochemical and Biophysical Research Communications·Wilai NoonpakdeePrapon Wilairat
Apr 25, 1997·Biochemical Pharmacology·D R ShawS Agrawal
Apr 19, 1997·Lancet·A WebbZ Dziewanowska
Jun 14, 2003·Pharmacology & Therapeutics·Kathleen F PirolloEsther H Chang
Apr 16, 1998·Pharmacology & Therapeutics·S Agrawal, R P Iyer
Mar 31, 2000·Pharmacology & Therapeutics·M Giraud-Panis, M Leng
Jan 19, 2000·Trends in Pharmacological Sciences·K J Myers, N M Dean
Nov 7, 2000·International Journal of Pharmaceutics·B R JastiX Li
Oct 24, 2002·Bioorganic & Medicinal Chemistry Letters·Alexander KarpeiskyLeonid Beigelman
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·E R KandimallaS Agrawal
Mar 12, 2003·Bioorganic & Medicinal Chemistry·Nikhil U MoheManikrao M Salunkhe
Sep 16, 1998·Current Opinion in Chemical Biology·S Agrawal, Q Zhao
Aug 1, 2000·Pharmaceutical Science & Technology Today·C D Partidos
Oct 3, 2002·RNA·Aleksandr V MakeyevStephen A Liebhaber
Apr 3, 1999·British Journal of Pharmacology·J PanésD N Granger
Sep 13, 2000·Antisense & Nucleic Acid Drug Development·C Ghosh, P L Iversen
Jun 1, 1997·Antisense & Nucleic Acid Drug Development·R B Diasio, R Zhang
Jun 1, 1997·Antisense & Nucleic Acid Drug Development·S AgrawalR Zhang
Aug 1, 1997·Antisense & Nucleic Acid Drug Development·R Häner, J Hall
Aug 27, 1999·Antisense & Nucleic Acid Drug Development·S SeidmanH Soreq
Apr 7, 1999·Antisense & Nucleic Acid Drug Development·V K Rait, B R Shaw
May 11, 2000·Antisense & Nucleic Acid Drug Development·S NakajimaM Hashida
May 22, 1998·Molecular Biology of the Cell·P LorenzD L Spector

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.